CureVac announces resolution of patent litigation with Pfizer/BioNTech

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-08 12:00 GMT | Update On 2025-08-08 12:03 GMT

CureVac N.V., a multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), has announced that CureVac N.V. and an affiliate (together, “CureVac”), and an affiliate of GSK plc have entered into agreements with BioNTech SE and an affiliate (together, “BioNTech”) and Pfizer, Inc. to resolve and dismiss all pending patent litigation in the United States between the companies related to mRNA-based COVID-19 vaccines and to set a framework for resolving ongoing patent disputes outside the US upon closing of BioNTech’s acquisition of CureVac announced on June 12, 2025.

Under the terms of the agreements, CureVac and GSK will receive in aggregate a payment of $740 million as well as single-digit royalties on sales of COVID-19 vaccines in the United States going forward. Additionally, CureVac will receive $50 million from GSK for monetizing a portion of U.S. product royalties due under its existing license agreement announced on July 3, 2024.

Furthermore, as part of the settlement agreements, CureVac will grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import into the U.S. and sell mRNA-based COVID-19 and/or influenza products. Such non-exclusive license will be expanded into a worldwide license upon the closing of BioNTech’s acquisition of CureVac.

Subject to regulatory approval, BioNTech’s acquisition of CureVac as announced on June 12, 2025 will be implemented as planned and its terms will remain unaffected.

CureVac is a multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized precision immunotherapy candidates to treat cancer. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CureVac announces resolution of patent litigation with Pfizer/BioNTech

Similar News

SC Quashes Substandard Rabeprazole Case Against Indica Labs, Cites Limitation Bar

NPPA Revises Ceiling Prices of Essential Drugs Including Riboflavin, Dialysis Solutions, Others; Details

NIT Rourkela Patents Pumpkin Petal-Silk Protein Formulation for Skin Cancer Treatment

CDSCO Panel Asks Astellas Pharma to Update Enzalutamide Label After Phase IV Study

Lupin gets tentative USFDA nod for HIV drug

Pfizer to buy obesity drug maker Metsera

Intas Pharma Told to Revise Phase I, III Pembrolizumab Trial Protocol

Sanofi SAR446268 wins USFDA fast track designation for non-congenital myotonic dystrophy type 1